|
1
|
Kosary C and McLaughlin J: Kidney and
renal pelvis. Cancer Statistics Review: 1973–1990. Miller BA, Ries
LAG, Hankey BE, et al: National Institutes Of Health; Bethesda: pp.
x1–x22. 1993
|
|
2
|
Fleming S and Lewi H: Collecting duct
carcinoma of the kidney. Histopathology. 10:1131–1141. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thoenes W, Störkel S and Rumpelt H:
Histopathology and classification of renal cell tumors (adenomas,
oncocytomas and carcinomas). The basic cytological and
histopathological elements and their use for diagnostics. Pathol
Res Pract. 181:125–143. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pisani P, Parkin D and Ferlay J: Estimates
of the worldwide mortality from eighteen major cancers in 1985.
Implications for prevention and projections of future burden. Int J
Cancer. 55:891–903. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ritchie A and Chisholm G: The natural
history of renal carcinoma. Semin Oncol. 10:390–400.
1983.PubMed/NCBI
|
|
6
|
Wood SL and Brown JE: Skeletal metastasis
in renal cell carcinoma: current and future management options.
Cancer Treat Rev. 38:284–291. 2012. View Article : Google Scholar
|
|
7
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Erdoğan F, Demirel A and Polat O:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Int J Clin Pract. 58:333–336. 2004. View Article : Google Scholar
|
|
9
|
Wang J, Chen A, Yang C, Zeng H, Qi J and
Guo FJ: A bone-seeking clone exhibits different biological
properties from the ACHN parental human renal cell carcinoma in
vivo and in vitro. Oncol Rep. 27:1104–1110. 2012.
|
|
10
|
Gibson WT, Hood RL, Zhan SH, et al; FORGE
Canada Consortium. Mutations in EZH2 cause Weaver syndrome. Am J
Hum Genet. 90:110–118. 2012. View Article : Google Scholar :
|
|
11
|
Weaver DD, Graham CB, Thomas I and Smith
DW: A new overgrowth syndrome with accelerated skeletal maturation,
unusual facies, and camptodactyly. J Pediatr. 84:547–552. 1974.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kleer CG, Cao Q, Varambally S, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kehinde EO, Maghrebi M and Anim JT: The
importance of determining the aggressiveness of prostate cancer
using serum and tissue molecular markers. Can J Urol. 15:3967–3974.
2008.PubMed/NCBI
|
|
14
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Varambally S, Cao Q, Mani RS, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen L, Cui J, Liang S, Pang Y and Liu P:
Update of research on the role of EZH2 in cancer progression. Onco
Targets Ther. 6:321–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagase H and Woessner JF Jr: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi SR, Key ME and Kalra KL: Antigen
retrieval in formalin-fixed, paraffin-embedded tissues: an
enhancement method for immunohistochemical staining based on
microwave oven heating of tissue sections. J Histochem Cytochem.
39:741–748. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nguyen DX and Massagué J: Genetic
determinants of cancer metastasis. Nat Rev Genet. 8:341–352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong GS and Rustgi AK: Matricellular
proteins: priming the tumour microenvironment for cancer
development and metastasis. Br J Cancer. 108:755–761. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Drabsch Y and ten Dijke P: TGF-β signaling
in breast cancer cell invasion and bone metastasis. J Mammary Gland
Biol Neoplasia. 16:97–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zlotnik A, Burkhardt AM and Homey B:
Homeostatic chemokine receptors and organ-specific metastasis. Nat
Rev Immunol. 11:597–606. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen H, Rossier C and Antonarakis SE:
Cloning of a human homolog of the Drosophila enhancer of zeste gene
(EZH2) that maps to chromosome 21q22.2. Genomics. 38:30–37. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cardoso C, Timsit S, Villard L,
Khrestchatisky M, Fontès M and Colleaux L: Specific interaction
between the XNP/ATR-X gene product and the SET domain of the human
EZH2 protein. Hum Mol Genet. 7:679–684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heinen A, Tzekova N, Graffmann N, et al:
Histone methyltransferase enhancer of zeste homolog 2 regulates
Schwann cell differentiation. Glia. 60:1696–1708. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xia H, Yu CH, Zhang Y, et al: EZH2
silencing with RNAi enhances irradiation-induced inhibition of
human lung cancer growth in vitro and in vivo. Oncol Lett.
4:135–140. 2012.PubMed/NCBI
|
|
27
|
Cho HM, Jeon HS, Lee SY, et al:
microRNA-101 inhibits lung cancer invasion through the regulation
of enhancer of zeste homolog 2. Exp Ther Med. 2:963–967. 2011.
|
|
28
|
Kikuchi J, Takashina T, Kinoshita I, et
al: Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of
the histone methyltransferase EZH2, inhibits growth of non-small
cell lung cancer cells. Lung Cancer. 78:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marchesi I, Fiorentino FP, Rizzolio F,
Giordano A and Bagella L: The ablation of EZH2 uncovers its crucial
role in rhabdomyosarcoma formation. Cell Cycle. 11:3828–3836. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou J, Roh JW, Bandyopadhyay S, et al:
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal
adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol
Oncol. 128:344–348. 2013. View Article : Google Scholar
|
|
31
|
Wan L, Li X, Shen H and Bai X:
Quantitative analysis of EZH2 expression and its correlations with
lung cancer patients’ clinical pathological characteristics. Clin
Transl Oncol. 15:132–138. 2013. View Article : Google Scholar
|
|
32
|
Zhang R, Wang R, Chang H, et al:
Downregulation of Ezh2 expression by RNA interference induces cell
cycle arrest in the G0/G1 phase and apoptosis in U87 human glioma
cells. Oncol Rep. 28:2278–2284. 2012.PubMed/NCBI
|
|
33
|
Wagener N, Macher-Goeppinger S, Pritsch M,
et al: Enhancer of zeste homolog 2 (EZH2) expression is an
independent prognostic factor in renal cell carcinoma. BMC Cancer.
10:5242010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wagener N, Holland D, Bulkescher J, et al:
The enhancer of zeste homolog 2 gene contributes to cell
proliferation and apoptosis resistance in renal cell carcinoma
cells. Int J Cancer. 123:1545–1550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hinz S, Weikert S, Magheli A, et al:
Expression profile of the polycomb group protein enhancer of Zeste
homologue 2 and its prognostic relevance in renal cell carcinoma. J
Urol. 182:2920–2925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sakurai T, Bilim VN, Ugolkov AV, et al:
The enhancer of zeste homolog 2 (EZH2), a potential therapeutic
target, is regulated by miR-101 in renal cancer cells. Biochem
Biophys Res Commun. 422:607–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li K, Chen MK, Situ J, et al: Role of
co-expression of c-Myc, EZH2 and p27 in prognosis of prostate
cancer patients after surgery. Chin Med J (Engl). 126:82–87.
2013.
|
|
38
|
Yang YA and Yu J: EZH2, an epigenetic
driver of prostate cancer. Protein Cell. 4:331–341. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takeshita F, Minakuchi Y, Nagahara S, et
al: Efficient delivery of small interfering RNA to bone-metastatic
tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA.
102:12177–12182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Voorzanger-Rousselot N, Juillet F, Mareau
E, Zimmermann J, Kalebic T and Garnero P: Association of 12 serum
biochemical markers of angiogenesis, tumour invasion and bone
turnover with bone metastases from breast cancer: a crossectional
and longitudinal evaluation. Br J Cancer. 95:506–514. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Andela VB, Gordon AH, Zotalis G, et al:
NFkappaB: a pivotal transcription factor in prostate cancer
metastasis to bone. Clin Orthop Relat Res. (415 Suppl): S75–S85.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lhoták S, Elavathil LJ, Vukmirović-Popović
S, Duivenvoorden WC, Tozer RG and Singh G: Immunolocalization of
matrix metalloproteinases and their inhibitors in clinical
specimens of bone metastasis from breast carcinoma. Clin Exp
Metastasis. 18:463–470. 2000. View Article : Google Scholar
|
|
43
|
Yoneda T, Sasaki A, Dunstan C, et al:
Inhibition of osteolytic bone metastasis of breast cancer by
combined treatment with the bisphosphonate ibandronate and tissue
inhibitor of the matrix metalloproteinase-2. J Clin Invest.
99:2509–2517. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hsu CH, Peng KL, Kang ML, et al: TET1
suppresses cancer invasion by activating the tissue inhibitors of
metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shin YJ and Kim JH: The role of EZH2 in
the regulation of the activity of matrix metalloproteinases in
prostate cancer cells. PloS One. 7:e303932012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fornari F, Milazzo M, Chieco P, et al: In
hepatocellular carcinoma miR-519d is upregulated by p53 and DNA
hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J
Pathol. 227:275–285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Matsusaka K, Kaneda A, Nagae G, et al:
Classification of Epstein-Barr virus-positive gastric cancers by
definition of DNA methylation epigenotypes. Cancer Res.
71:7187–7197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hervouet E, Vallette FM and Cartron PF:
Dnmt3/transcription factor interactions as crucial players in
targeted DNA methylation. Epigenetics. 4:487–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Martinez R, Schackert G and Esteller M:
Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic
importance in glioblastoma multiforme. J Neurooncol. 82:133–139.
2007. View Article : Google Scholar
|
|
50
|
Chu LC, Eberhart CG, Grossman SA and
Herman JG: Epigenetic silencing of multiple genes in primary CNS
lymphoma. Int J Cancer. 119:2487–2491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Crea F, Fornaro L, Bocci G, et al: EZH2
inhibition: targeting the crossroad of tumor invasion and
angiogenesis. Cancer Metastasis Rev. 31:753–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
